A Phase 1 study of the highly-selective RET Inhibitor, BLU-667, in patients with thyroid cancer, non-small cell lung cancer (NSCLC) and other advanced solid tumors

UCI-16-96
UCI-16-96
NCT03037385
Cancer - Lung, Cancer - Thyroid
Viola W. Zhu, MD
Viola W. Zhu, MD
Open
Treatment
BLU-667
1
Adult
Local

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.